Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Researchers are in the midst of a breakthrough treatment for Fragile X syndrome

Staff Writer
Staff Writer 2 years ago
Updated 2021/05/12 at 6:34 PM
Share
SHARE

Researchers at the University at Buffalo in collaboration with Tetra Therapeutics made a major advancement toward a breakthrough treatment for Fragile X syndrome, according to new results from a phase 2 clinical study.

Known as BPN14770, the treatment is purportedly being tested for its role in improving cognitive function among patients with Fragile X syndrome, a genetic condition associated with the development of autism.

The drug’s primary mechanism of action involves the inhibition of the enzyme phosphodiesterase‐4D.

The research team demonstrated that the drug is safe and well-tolerated, while drastically improving cognitive functions in the brain.

“In addition to being safe and well-tolerated, treatment with BPN14770 led to significant cognitive improvement, specifically in the language domains, and we also saw a clinically meaningful benefit in overall daily functioning,” the study reads.

“These findings validate our approach to treating this disease through a mechanism that addresses a core deficit in the disorder.”

The study was funded by the nonprofit organization FRAXA Research Foundation.

Photo: CDC

You Might Also Like

Study finds mental distress affects almost half of all teenage females in Norway

ICD-11 lists complex post-traumatic stress disorder as a new condition

New research identifies personality traits linked to cognitive deficits

Many known biological pathways in the brain are impacted by Alzheimer’s disease

Immune system and CNS may play a major role in ALS

TAGGED: BPN14770, Fragile X syndrome, autism, cognition
Staff Writer December 12, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Black Americans see social media as detrimental for political activism
Next Article Remdesivir and baricitinib taken in conjunction demonstrates efficiency toward combating COVID-19

Recommended

Clinical

Study finds mental distress affects almost half of all teenage females in Norway

1 Min Read
Clinical

ICD-11 lists complex post-traumatic stress disorder as a new condition

1 Min Read
Clinical

New research identifies personality traits linked to cognitive deficits

1 Min Read
Clinical

Many known biological pathways in the brain are impacted by Alzheimer’s disease

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?